Abiraterone acetate delays quality of life decline in men with metastatic prostate cancer

Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.

Fuente : http://www.eurekalert.org/pub_releases/2013-09/uon…